Looking at the Latest Data in Multiple Myeloma and Lymphoma From ASH 2023: Drs Landgren and Saeed
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
EP: 1.Making the Most of New Data in MPN, Leukemia, and GVHD From ASH 2023: Drs Ponce and Hobbs
EP: 2.Looking at the Latest Data in Multiple Myeloma and Lymphoma From ASH 2023: Drs Landgren and Saeed
EP: 3.Taking Trial Data to the Clinic in MPN and CLL From ASH 2023: Drs Rogers, Brown, and Shammo
Today-
We are reporting from the 2023 ASH Annual Meeting!
Get ready for highlights of some of the top news presented each day during the meeting—and soon we’ll speak with Drs Hayder Saeed and Carl Ola Landgren to discuss some exciting research in lymphoma and multiple myeloma.
Welcome to OncLive News Network! I’m Caroline Seymour.
The combination of isatuximab-irfc (Sarclisa), carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Isa-KRd) significantly increased the rates of minimal residual disease (MRD) negativity at the 10-5 and 10-6 cutoffs post-consolidation vs carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma, according to findings from the phase 3 IsKia trial (NCT04483739).
The use of the BCMA-directed CAR T-cell therapy D8 Fab CAR and the dual-targeting AUTO8 CAR T-cell therapy proved safe and feasible in patients with relapsed/refractory multiple myeloma, according to early findings from the ongoing phase 1 MCARTY trial (NCT04795882).
Brentuximab vedotin (Adcetris) plus nivolumab (Opdivo), doxorubicin, and dacarbazine was found to have efficacy and acceptable safety and tolerability when used as a frontline treatment in patients with previously untreated advanced, classical Hodgkin lymphoma, according to data from the phase 2 SGN35-027 trial (NCT03646123).
Autologous hematopoietic cell transplantation (auto-HCT) lowered relapse and progression rates and improved survival outcomes vs CAR T-cell therapy in patients with relapsed large B-cell lymphoma (LBCL) who experienced complete remission (CR) with interim treatment, according to findings from a real-world, retrospective study.
Please be sure to check out more of our coverage from the 2023 ASH Annual Meeting at OncLive.com.
That’s all for today. Tomorrow, we’ll sit down with Drs Kerry Rogers, Jamie Shammo, and Jennifer Brown, who will share their insights on important data in chronic lymphocytic leukemia and MPNs.
Thank you for watching OncLive News Network: On Location, I’m Caroline Seymour.
